Stomach Cancer Trial, Recruiting NCT06102772 Sponsor: Tianjin Medical University Cancer Institute and Hospital Condition: Stomach Cancer
Back to Stomach Cancer

Stomach Cancer Trial, Recruiting

NCT06102772
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older
  • You are in generally good physical condition and able to carry out daily activities with little or no limitation (confirm with trial site regarding specific fitness scoring)
  • You have been diagnosed through a tissue biopsy with stomach cancer or cancer at the junction of the stomach and food pipe (gastroesophageal junction) that has spread or cannot be surgically removed
  • You have already received one round of chemotherapy for this cancer and it stopped working, OR you completed adjuvant (post-surgery) chemotherapy but your cancer came back or got worse within 6 months of finishing it
  • You have not previously been treated with immunotherapy drugs known as PD-1 or PD-L1 inhibitors
  • You have at least one measurable tumour that can be tracked during the trial (confirm with trial site)
  • Your blood, liver, and kidney function meet certain minimum health levels based on recent lab tests (confirm with trial site for specific values)
  • Your blood clotting function is within a normal range and you have no active bleeding
  • If you are a woman who could become pregnant, you must have a negative pregnancy test within 14 days before joining and agree to use reliable contraception during the trial and for 8 weeks after the last dose
  • If you are a man, you must either have had a sterilisation procedure or agree to use reliable contraception during the trial and for 8 weeks after the last dose
  • Your doctor expects you to live for at least 3 more months
  • You are willing to participate, have signed a consent form, and are able to attend all required follow-up visits

Who may not be able to join:

  • You have previously been treated with a type of drug called a VEGFR inhibitor
  • You have previously received the chemotherapy drug paclitaxel, unless you had it as part of pre- or post-surgery treatment and it ended more than 6 months before your cancer got worse
  • You have received a live vaccine within 4 weeks before joining, or may need one during the study
  • You have an active autoimmune disease, or have had one within the past 4 weeks
  • You have previously had a bone marrow transplant or an organ transplant from another person
  • You have high blood pressure that cannot be controlled with medication (generally a reading of 150/90 mmHg or higher)
  • You have a condition that affects how you absorb medicines, or you are unable to swallow pills
  • You have active stomach or intestinal problems such as ulcers, inflammatory bowel disease, or tumours that are actively bleeding, or other conditions that could lead to bleeding or a hole forming in the gut
  • You have had significant bleeding episodes in the last 3 months, or a stroke or similar blood clot event in the last 12 months
  • You have had a serious heart condition in the last 6 months, such as a heart attack, severe chest pain, or heart bypass surgery; or you have significant heart failure, certain irregular heart rhythms, or reduced heart pumping function
  • You have a serious active infection that is not under control
  • You are known to have HIV, active hepatitis B, or active hepatitis C infection
  • You have any other significant medical condition, abnormal test results, or health issue that the research doctor believes makes participation unsafe or unsuitable
  • The trial doctors consider you unsuitable for inclusion for any other reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Ting Deng, MD, Tianjin Medical University Cancer Institute and Hospital

Phone: 022-23340123

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Registry
ClinicalTrials.gov
Start date
10 November 2023
Est. completion
10 October 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Progression Free Survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov